Skip to the main content

Acta clinica Croatica, Vol. 56. No. 4., 2017.

Original scientific paper

https://doi.org/10.20471/acc.2017.56.04.14

Association of Pentraxin-3, Galectin-3 and Matrix Metalloproteinase-9/Timp-1 with Cardiovascular Risk in Renal Disease Patients

Milica Miljković ; Department of Medical Biochemistry, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia
Aleksandra Stefanović ; Department of Medical Biochemistry, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia
Nataša Bogavac-Stanojević ; Department of Medical Biochemistry, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia
Sanja Simić-Ogrizović ; Department of Nephrology, Clinical Center of Serbia, Belgrade, Serbia
Jerka Dumić ; Department of Medical Biochemistry, Faculty of Pharmacy and Biochemistry, University of Zagreb, Zagreb, Croatia
Darko Černe ; Department of Clinical Biochemistry, Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia
Zorana Jelić-Ivanović ; Department of Medical Biochemistry, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia
Jelena Kotur-Stevuljević ; Department of Medical Biochemistry, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia

Full text: english pdf 698 Kb

page 673-680

downloads: 802

cite

Abstract

Inflammation, apoptosis and extracellular remodeling play significant roles in cardiovascular disease (CVD) underlying the major causes of mortality in renal patients. In 19 pre-dialysis patients, 21 dialysis patients and 20 control subjects, the concentrations of pentraxin-3, galectin-3, MMP-9 and TIMP-1 were determined by ELISA. CVD risk was calculated according to the Framingham risk score algorithm. Pentraxin-3 was increased in renal patients compared to healthy controls (p<0.001). In contrast, galectin-3 was reduced in hemodialysis patients compared to pre-dialysis patients and controls (p<0.001). In addition, MMP-9 and TIMP-1 were elevated in renal patients compared to controls (p<0.01 and p<0.001, respectively). Logistic regression analyses disclosed associations of galectin-3, MMP-9, pentraxin-3 and glomerular filtration with calculated CVD risk score. Combined testing of pentraxin-3, galectin-3, MMP-9 and glomerular filtration rate can discriminate renal patients with high and low risk of a coronary event.

Keywords

Kidney diseases; Pentraxin-3; Galectin-3; Matrix-metalloproteinase-9; Tissue inhibitor of matrix metalloproteinase-1; Cardiovascular diseases

Hrčak ID:

195437

URI

https://hrcak.srce.hr/195437

Publication date:

15.12.2017.

Article data in other languages: croatian

Visits: 2.457 *